T1	Participants 692 765	2121/2292 patients (92.5%) had an analysable dataset for either biomarker
T2	Participants 776 784	patients
T3	Participants 848 856	patients
T4	Participants 970 978	patients
T5	Participants 1057 1065	patients
T6	Participants 1218 1226	patients
T7	Participants 1265 1273	patients
T8	Participants 1414 1422	patients
T9	Participants 1774 1782	patients
